Comparing monthly product prices among chemical subgroups showed that monoclonal antibodies were more expensive than protein kinase inhibitors, with median monthly product prices of CHF 7,412 (IQR = 5,281–8,501) versus CHF 4,674 (IQR = 4,058–5,965). Here, WEE1 is linked to congestive heart failure.